Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• The studies primarily included adults aged 27 to 68 years with mild-to-moderate onychomycosis, mainly treated in outpatient settings. Adverse events associated with treatments like luliconazole 5% solution included dry skin, paronychia, eczema, and hyperkeratosis, which generally improved or resolved post-treatment.
• Comparative studies did not specifically highlight differential effectiveness or safety outcomes among distinct population subgroups, indicating a need for further research to explore these aspects more thoroughly.
• Luliconazole 5% solution demonstrated low-quality evidence suggesting little or no difference in adverse events compared to the vehicle (relative risk (RR) 1.02, 95% confidence interval (CI) 0.90 to 1.16), with common adverse events including dry skin, paronychia, eczema, and hyperkeratosis, which improved or resolved after treatment.
• Efinaconazole 10% solution had a slightly higher risk of adverse events, such as dermatitis and vesicles (RR 1.10, 95% CI 1.01 to 1.20; high-quality evidence), while Tavaborole 5% solution likely presented a higher risk of application site reactions (RR 3.82, 95% CI 1.65 to 8.85; moderate-quality evidence).
• Adverse events related to luliconazole 5% solution included dry skin, paronychia, eczema, and hyperkeratosis, which were commonly reported but improved or resolved post-treatment.